SPEECH-PROCESSING
10.4.2024 09:03:28 CEST | Business Wire | Press release
Philips Dictation by Speech Processing Solutions, a globally leading innovator in voice technology, has announced the latest innovation in their professional cloud-based dictation and transcription solution, Philips SpeechLive. The enhancement integrates speech recognition from Nuance Dragon. This major development offers the most accurate dictation workflow, leading to new levels of efficiency for legal professionals worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410464123/en/
Philips SpeechLive with Nuance Dragon (Graphic: Business Wire)
Featuring highly precise AI-powered speech recognition integrated directly into legal workflows, this latest version of SpeechLive continuously learns for unmatched accuracy. It empowers time-constrained lawyers to create high-quality documentation while enhancing efficiency and expediting documentation completion. Additionally, assistants can access automated transcripts together with the original recordings for quick corrections, freeing them to concentrate on more meaningful tasks, ultimately boosting work satisfaction and productivity.
Dr. Thomas Brauner, CEO of Speech Processing Solutions, emphasized the significance of this partnership, stating, "The integration of Nuance Dragon into Philips SpeechLive marks a significant enhancement for legal professionals. By merging top-tier AI-powered speech recognition with the best-in-class dictation platform, we're empowering legal professionals to benefit from the best of both worlds. This unique combination will streamline their workflow and achieve new levels of efficiency and accuracy in their document creation process."
Key benefits for legal professionals include:
- Specialized Legal Vocabularies: Access tailored legal vocabularies for precise transcription and industry-specific terminology adherence.
- Custom Profiles: Personalize speech profiles to streamline workflows and boost efficiency, eliminating repetitive corrections.
- Personalized User Recognition: Nuance Dragon's adaptive learning optimizes transcription accuracy, tailoring to individual preferences.
- Enhanced Functionality: Experience streamlined features within SpeechLive, including live dictation and recording capabilities, enhancing workflow efficiency.
- Enhanced Mobility: Access SpeechLive across devices for flexible work arrangements, including PCs and mobile phones, facilitating work from any location.
- Real-time speech recognition with Dragon Bar: Dictate directly into applications for convenience, such as Word documents or Client Management Systems (CMS), simplifying the documentation process.
- Data Security: Philips SpeechLive prioritizes data security, with servers located in five regions worldwide and features such as Multifactor Authentication and Single Sign-on.
In the legal profession, effective communication requires reliance on and integration of precise speech recognition and a seamlessly integrated workflow system.
Philips SpeechLive platform's versatility and convenience cater to the dynamic needs of legal professionals. This all-in-one dictation and transcription platform empowers time-pressed professionals and high-demand firms to save time and earn more money by automating the documentation process between authors and transcriptionists, also allowing them to work flexibly from anywhere.
Free demos of Philips SpeechLive with Nuance Dragon integration are available at www.speechlive.com/dragon-speech-recognition.
About Speech Processing Solutions (SPS):
Speech Processing Solutions (SPS), the global leader in professional dictation solutions, is active in 50+ countries, with over 4 million users and a worldwide network of 1,000+ partners. It develops and markets industry-leading dictation and transcription solutions, automated documentation workflows with speech recognition, as well as award-winning dictation devices, sold under the Philips brand. SPS's mission is to empower every user to be more productive by simplifying their work with smart, voice-based solutions. Headquartered in Vienna, Austria, SPS has regional offices in Australia, Canada, Belgium, France, Germany, the United Kingdom, and the United States.
Follow Us:
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
YouTube: http://www.youtube.com/philipsdictation
Facebook: https://www.facebook.com/philipsdictation
Instagram: https://www.instagram.com/philips_dictation/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410464123/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release
Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release
Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp
KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release
Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen
Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release
Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom